查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1926795

医药温控包装市场：依包装类型、温度范围、运输方式、隔热材料、应用和最终用户划分－2026-2032年全球预测

Temperature Controlled Package for Pharmaceutical Market by Packaging Type, Temperature Range, Shipping Mode, Insulation Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，医药温控包装市场规模将达到 42 亿美元，到 2026 年将成长至 43.7 亿美元，到 2032 年将达到 60 亿美元，复合年增长率为 5.23%。

关键市场统计数据
基准年 2025 42亿美元
预计年份：2026年 43.7亿美元
预测年份 2032 60亿美元
复合年增长率 (%) 5.23%

一份全面说明，阐述温控包装在整个医药供应链中的战略作用：热完整性、可追溯性和操作适用性

随着复杂生物製药和温度敏感治疗方法的激增，药品低温运输已成为现代医疗物流的关键组成部分。温控包装的完整性不再是后勤部门事务，而是维持产品疗效、支持合规性以及在全球分销网络中保护商业性价值的战略要素。本文概述了影响包装选择、合格和实施的技术、营运和监管因素，从而对市场格局进行了分析。

数位化、混合热处理技术、永续性要求和更高的验证标准正在重新定义药品低温运输包装方案。

温控药品包装领域正经历一场变革性的转变，重塑采购、设计和监管方式。数位化和互联感测器实现了连续的温度和衝击监测，使认证流程从逐批次抽查转变为持续检验模式，从而显着降低了风险。同时，合格和被动式技术的整合催生了混合解决方案，将相变材料与电子控製冷却相结合，以满足先进生物製药日益严格的温度控制要求。

评估2025年美国关税调整对营运和采购的综合影响，以及这些影响对供应链韧性和包装策略调整的影响

2025年美国政策变迁和关税措施正在对全球供应链产生累积效应，影响筹资策略、运输方式选择和包装经济效益。关税带来的成本压力促使许多相关人员重新评估其供应商结构，并加速关键包装组件多元化，减少对单一海外製造来源的依赖。这种转变对前置作业时间、合格要求和库存策略等下游环节产生影响，因为企业需要寻求更具韧性的方案来应对成本波动，同时维持产品品质。

全面的細項分析揭示了包装类型、温度曲线、应用案例、最终用户需求、运输方式和隔热材料选择如何驱动差异化策略。

有效的市场区隔分析能够揭示创新和投资能带来最大回报的领域。要理解这个市场需要从多个交织的观点。基于包装类型的市场区隔可以将包装分为主动式和被动式。主动式解决方案包括电冷却器、相变材料和冷冻装置，而被动式解决方案包括干冰、发泡隔热材料和冰袋。每种方案都有不同的检验要求、能耗和可重复使用性，这些都会影响其在特定货物上的选择。基于温度范围的分类可以将运输分为常温运输、冷冻运输和冷藏运输，从而产生不同的热性能标准、认证计划和监控要求，这些要求必须与货物稳定性要求相一致。

区域差异和市场动态（美洲、欧洲、中东和非洲、亚太地区）会影响包装材料的选择、检验优先顺序和分销模式。

区域趋势影响着温控包装的规格、采购和运营，地域差异体现在法规结构、基础设施成熟度和物流网路等方面。在美洲，先进的低温运输基础设施以及对生物製药和特殊治疗药物的高需求，推动了先进主动式系统和整合监测解决方案的应用，区域中心则成为合格测试和创新的中心。美洲内部的跨境贸易也影响库存布局和分销模式，迫使跨国公司调整其包装策略，以符合监管要求和商业流通。

成熟製造商、材料创新者和物流服务供应商之间竞争与合作的动态，正在塑造整合化、检验的解决方案和上市时间差异化优势。

温控药品包装领域的竞争格局呈现出多元化的特点，既有成熟的製造商，也有技术创新者和以物流为中心的服务供应商，各方透过伙伴关係和策略联盟进行协作。现有包装供应商专注于规模化生产、检验的设计方案和全球分销网络，以帮助製造商获得认证；而新参与企业则利用材料科学和物联网技术的进步，推出更轻、可重复使用性更高、数据驱动的系统。随着客户对产品性能的持续需求以及对多段运输路线可视性的日益重视，这些不同的策略正在逐渐整合。

透过数位化遥测、供应商多元化、循环系统实施和跨职能管治，为经营团队提供加强低温运输韧性的实际可行的策略行动

产业领导者应采取一系列切实有效、影响深远的措施，以增强低温运输韧性并获得竞争优势。首先，透过投资数位化遥测和持续监控能力，将间歇性检验转变为持续保障。此类系统能够降低风险，并为异常情况管理提供可操作的洞察。其次，实现关键隔热材料和主动冷却组件供应商的多元化，以降低受贸易政策波动和单一供应来源中断的影响。最后，建立预先认证的替代设计方案，以便在需要时快速替换。

一项结合相关人员访谈、技术审查、情境分析和实验室通讯协定评估的深入混合方法研究途径，确保了研究结果的严谨性和可操作性。

本分析的调查方法结合了定性和定量方法，旨在得出可靠且实用的结论。主要研究工作包括对各类相关人员进行结构化访谈，例如包装工程师、品质保证经理、物流负责人和采购主管，以获取有关营运限制、检验方法和供应商选择标准的第一手资料。此外，还对包装规格、测试报告和案例研究进行了技术审查，以展示包装在各种运输条件下的运作性能。

将策略要求整合起来，强调检验的绩效、持续监控、供应商柔软性和生命週期思维，以此作为差异化优势。

总之，温控包装是一项至关重要的策略能力，需要材料科学、物流设计、监管策略和商业规划等多面向进行整合思考。在复杂生物製药和疫苗需求的推动下，该领域正经历快速创新。同时，2025年的政策变化和关税趋势凸显了供应链敏捷性和供应商多元化的重要性。采用多层次细分方法进行包装决策——综合评估包装类型、温度范围、应用、最终用户需求、运输方式和隔热材料——能够帮助企业客製化既能保护产品完整性又能符合实际营运需求的解决方案。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依包装类型分類的药品温控包装市场

  • 活性包装
    • 电冷却器
    • 相变材料
    • 冷冻机组
  • 被动式封装
    • 干冰
    • 发泡隔热材料
    • 凝胶包

9. 依温度范围分類的药品温控包装市场

  • 管制室温
  • 冷冻
  • 冷藏

第十章：以运输方式分類的药品温控包装市场

  • 航空邮件
  • 陆运
  • 海运

第十一章：以隔热材料分類的医药温控包装市场

  • 发泡聚苯乙烯
  • 凝胶包插入物
  • 聚氨酯泡棉
  • 真空绝热板

第十二章：按应用分類的医药温控包装市场

  • 生物製药
    • 单株抗体
    • 重组蛋白
  • 胰岛素
  • 无菌注射剂
  • 疫苗
    • mRNA疫苗
    • 蛋白质次单元疫苗
    • 病毒载体疫苗

第十三章：依最终用户分類的药品温控包装市场

  • 合约研究机构
  • 医疗机构
  • 物流运营商
  • 製药公司

第十四章：按地区分類的药品温控包装市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：依组别分類的药品温控包装市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：各国药品温控包装市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国药品温控包装市场

第十八章：中国医药温控包装市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Air Liquide SA
  • Cold Chain Technologies, LLC
  • Cryopak Industries Inc.
  • Cryoport, Inc
  • Envirotainer AB
  • Pelican Products, Inc
  • Sealed Air Corporation
  • Softbox Solutions Ltd
  • Sonoco Products Company
  • Thermo Fisher Scientific Inc.
  • Va-Q-tec AG
  • World Courier, Inc.
Product Code: MRR-4F7A6D4FF2FA

The Temperature Controlled Package for Pharmaceutical Market was valued at USD 4.20 billion in 2025 and is projected to grow to USD 4.37 billion in 2026, with a CAGR of 5.23%, reaching USD 6.00 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.20 billion
Estimated Year [2026] USD 4.37 billion
Forecast Year [2032] USD 6.00 billion
CAGR (%) 5.23%

Comprehensive orientation to temperature controlled packaging articulating the strategic role of thermal integrity, traceability, and operational fit across pharmaceutical supply chains

The pharmaceutical cold chain has emerged as a defining element of modern healthcare logistics, driven by the proliferation of complex biologics and temperature-sensitive therapies. The integrity of temperature controlled packaging is no longer a back-office concern; it is a strategic enabler that preserves product efficacy, underpins regulatory compliance, and protects commercial value throughout global distribution networks. This introduction frames the market context by outlining the technical, operational, and regulatory forces shaping packaging selection, qualification, and deployment.

Advances in life sciences have increased the volume and variety of products that require precise thermal management during storage and transit. Concomitantly, logistics networks are adapting to handle shorter lead times, multi-modal movements, and geographically dispersed manufacturing footprints. These dynamics compel stakeholders to rethink traditional packaging paradigms and to invest in solutions that deliver repeatable temperature control, traceability, and validated performance across the entire journey from factory to patient.

Consequently, organizations must evaluate packaging through a multidimensional lens: thermal performance under real-world transit stress, compatibility with payloads such as monoclonal antibodies and mRNA vaccines, operational fit with air, ground, and ocean transport, and sustainability profiles that reflect growing environmental scrutiny. This introduction sets the stage for a deeper examination of transformative shifts, tariff impacts, segmentation intelligence, regional variation, supplier dynamics, and practical recommendations for industry leaders.

How digitalization, hybrid thermal technologies, sustainability imperatives, and heightened validation standards are redefining pharmaceutical cold chain packaging choices

The landscape for temperature controlled pharmaceutical packaging is undergoing transformative shifts that are reshaping procurement, engineering, and regulatory approaches. Digitalization and connected sensors now enable continuous temperature and shock monitoring, moving qualification from batch-based spot checks to continuous verification models that materially reduce risk. At the same time, the convergence of active and passive technologies provides hybrid solutions that combine phase change materials with electronically controlled cooling to meet increasingly narrow thermal envelopes demanded by advanced biologics.

Sustainability considerations are also prompting material innovation and lifecycle thinking. Insulation technologies such as vacuum insulated panels and advanced polyurethane alternatives are being evaluated not only for thermal efficiency but also for recyclability and end-of-life impact. These forces are further accentuated by operational changes: last-mile delivery complexities require modular, reusable packaging systems that can be integrated with cold storage hubs or micro-fulfillment centers, while expanded use of air freight for time-critical shipments favors lightweight, high-performance systems.

Regulatory rigor and validation expectations have intensified, driving standardized protocols for thermal performance and increasing demand for third-party test evidence. Taken together, these shifts require multidisciplinary responses that combine material science, data analytics, logistics design, and regulatory expertise to maintain product quality and manage total cost of ownership over repeated use cycles.

Assessing the combined operational and procurement consequences of 2025 United States tariff changes and their effects on supply resilience and packaging strategy adaptation

Policy changes and tariff measures in the United States in 2025 have exerted cumulative effects across global supply chains, influencing sourcing strategies, modal selection, and packaging economics. Tariff-driven cost pressures have encouraged many stakeholders to reassess supplier footprints and to accelerate diversification away from single-source overseas manufacturing for critical packaging components. This reorientation has downstream implications for lead times, qualification requirements, and inventory strategies as organizations seek resilient options that preserve quality while managing cost volatility.

Tariff impacts have also altered modal calculus, with some shippers favoring modes that reduce exposure to tariff-sensitive transits or that allow consolidation strategies to absorb incremental costs. Consequently, packaging requirements are evolving to support longer transit durations or to enable protective buffering when routing changes extend in-transit time. Procurement teams are increasingly focused on total landed cost considerations that include tariff exposure, customs handling, and potential rework or requalification costs tied to component substitutions.

At the same time, tariff uncertainty has catalyzed closer collaboration between packaging manufacturers, logistics providers, and pharmaceutical customers to design flexible supply arrangements. These arrangements often involve localized manufacturing of critical insulation components, strategic inventory hubs positioned to minimize tariff impacts, and contractual clauses that share the burden of sudden policy shifts. While tariffs add complexity, they also incentivize investments in agility, regionalized sourcing, and validated alternative materials and designs that can be deployed rapidly if trade conditions change.

Holistic segmentation analysis revealing how packaging type, temperature profile, application use case, end-user requirements, shipping mode, and insulation selection drive differentiated strategies

Effective segmentation analysis illuminates where innovation and investment will yield the greatest returns, and this market should be understood through multiple intersecting lenses. Based on Packaging Type, the market divides into Active Packaging and Passive Packaging, with Active solutions including electric coolers, phase change materials, and refrigeration units and Passive solutions encompassing dry ice, foam insulation, and gel packs; each choice carries different validation, energy, and reuse profiles that influence selection for a given payload. Based on Temperature Range, distinctions among controlled ambient, frozen, and refrigerated shipments dictate thermal performance criteria, qualification timelines, and monitoring expectations that must align with payload stability requirements.

Further granularity is provided by Application segmentation, where biologics, insulin, sterile injectables, and vaccines present distinct handling protocols and regulatory scrutiny. Within biologics, monoclonal antibodies and recombinant proteins often require narrow temperature control and gentle handling, while vaccine categories such as mRNA vaccines, protein subunit vaccines, and viral vector vaccines each impose unique cold chain demands that affect both packaging architecture and monitoring strategies. Based on End User, contract research organizations, healthcare facilities, logistics providers, and pharmaceutical manufacturers exercise different priorities: CROs emphasize sample integrity and traceability, healthcare facilities prioritize last-mile simplicity, logistics providers focus on durability and return logistics, and manufacturers seek validated scalability.

Considerations around Shipping Mode, including air freight, ground transportation, and sea freight, influence container design, shock resistance, and insulation thickness, while choices of Insulation Material - expanded polystyrene, gel pack inserts, polyurethane foam, and vacuum insulated panels - reflect tradeoffs between thermal efficiency, weight, cost, and sustainability. When these segmentation layers are overlaid, it becomes evident that optimal packaging strategies are highly contextual, requiring cross-functional evaluation of payload sensitivity, transit profile, regulatory constraints, and total lifecycle implications.

Regional differentiation and market dynamics across the Americas, Europe Middle East and Africa, and Asia Pacific that influence packaging selection, validation priorities, and distribution models

Regional dynamics shape how temperature controlled packaging is specified, procured, and operated, with geographic differences manifesting in regulatory frameworks, infrastructure maturity, and logistics networks. In the Americas, advanced cold chain infrastructure and high demand for biologics and specialty therapies drive the adoption of sophisticated active systems and integrated monitoring solutions, while regional hubs serve as centers for qualification testing and innovation. Cross-border trade within the hemisphere also influences inventory placement and distribution models, prompting multinational firms to calibrate packaging strategies to both regulatory expectations and commercial flows.

Europe, Middle East & Africa presents a mosaic of regulatory regimes and infrastructure capabilities. Western European markets often lead on sustainability requirements and advanced validation standards, encouraging investment in reusable systems and higher-efficiency insulation. In contrast, emerging markets within the region may place a premium on robustness and simplicity to manage variable transit conditions and intermittent cold storage availability. Consequently, packaging solutions that support modular validation and adaptable thermal performance can bridge performance expectations across disparate operating contexts.

Asia-Pacific exhibits rapid growth in pharmaceutical manufacturing and export activity, which elevates demand for packaging solutions that support long-haul air and sea shipments and that integrate with regional aggregation facilities. The region's supply base is also a source of material and component innovation, but differences in standards and testing practices require careful alignment to importing-market qualification requirements. Across all regions, local regulatory engagement, infrastructure assessment, and close collaboration with regional logistics partners are essential to ensure reliable cold chain performance.

Competitive and collaborative dynamics among established manufacturers, material innovators, and logistics service providers shaping integrated validated solutions and go-to-market differentiation

The competitive landscape in temperature controlled pharmaceutical packaging is characterized by a mix of established manufacturers, technology innovators, and logistics-centric service providers that are increasingly cooperating through partnerships and strategic alliances. Established packaging vendors focus on scale, validated designs, and global distribution networks that support manufacturer qualification, while newer entrants leverage materials science advances and IoT capabilities to introduce lighter, more reusable, and data-driven systems. These divergent approaches are converging as customers demand both proven performance and enhanced visibility across multi-leg journeys.

Service differentiation is emerging around end-to-end offerings where companies combine packaging hardware with monitoring-as-a-service, reverse logistics, and validation support, enabling customers to outsource complex qualification and operational responsibilities. Strategic collaborations between packaging suppliers and third-party logistics providers are producing turnkey solutions tailored for specific applications such as high-value biologics or temperature-critical vaccine distribution. Meanwhile, partnerships with research institutions and standards bodies accelerate the development of test protocols and cross-industry validation frameworks that reduce time-to-adoption for new materials and designs.

Investment patterns indicate a focus on modularity and scalability, with firms prioritizing assets that can be rapidly reconfigured for different payload classes and transport modes. Intellectual property around phase change formulations, vacuum panel construction, and sensor integration differentiates suppliers, but commercial success increasingly depends on service reliability, validated performance history, and the ability to support complex regulatory submissions for pharmaceutical customers.

Practical strategic actions for executives to strengthen cold chain resilience through digital telemetry, supplier diversification, circularity pilots, and cross-functional governance

Industry leaders should pursue a set of pragmatic, high-impact actions to strengthen cold chain resilience and capture competitive advantage. First, invest in digital telemetry and continuous monitoring capabilities to transition from episodic validation to continuous assurance; such systems reduce risk and provide actionable insights for exception management. Second, diversify supplier bases for critical insulation materials and active cooling components to mitigate exposure to trade policy shocks and single-source disruptions, and establish prequalified alternative designs to expedite substitution when necessary.

Third, prioritize lifecycle assessments and circularity in packaging selection by piloting reusable systems where return logistics are feasible and by evaluating the tradeoffs between single-use simplicity and reusable system economics. Fourth, align packaging qualification protocols with regulatory expectations early in the product development cycle, integrating real-world transit simulation and laboratory validation to avoid costly rework. Fifth, build cross-functional governance that brings procurement, quality, engineering, and logistics into a joint decision-making process so that thermal performance, cost, and operational feasibility are considered holistically.

Finally, engage proactively with regional logistics partners and regulatory stakeholders to shape standards and accelerate mutual recognition of validation evidence. Establishing collaborative pilots with carriers and healthcare providers can demonstrate reliability in last-mile contexts and support scalable rollouts. These recommendations emphasize pragmatic investment, governance, and partnerships as the foundation for maintaining product integrity while managing commercial imperatives.

Detailed mixed-methods research approach combining stakeholder interviews, technical review, scenario analysis, and laboratory protocol assessment to ensure rigorous actionable findings

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure robust, actionable conclusions. Primary research involved structured interviews with a cross-section of stakeholders including packaging engineers, quality assurance leaders, logistics operators, and procurement executives, providing firsthand insights into operational constraints, validation practices, and vendor selection criteria. These interviews were complemented by technical reviews of packaging specifications, test reports, and case studies that illustrate real-world performance under varied transit conditions.

Secondary research encompassed a systematic review of peer-reviewed literature, regulatory guidance documents, and industry white papers that inform current best practices in thermal management and cold chain validation. Where appropriate, laboratory test protocols and performance standards were referenced to evaluate insulation materials, phase change formulations, and active cooling units. Data triangulation techniques were applied to reconcile differing perspectives and to validate recurring themes across sources.

Analytical methods included scenario analysis to probe the effects of tariff shifts, modal changes, and product mix evolution, as well as sensitivity testing of operational assumptions such as transit duration and return logistics feasibility. Limitations of the study are clearly documented, including areas where emerging technologies require longer-term field validation, and the report highlights opportunities for targeted follow-up research to close evidence gaps and validate pilot deployments.

Synthesis of strategic imperatives highlighting validated performance, continuous monitoring, supplier flexibility, and lifecycle thinking as differentiators for cold chain success

In conclusion, temperature controlled packaging is a critical strategic capability that requires integrated thinking across materials science, logistics design, regulatory strategy, and commercial planning. The sector is experiencing rapid innovation driven by the needs of complex biologics and vaccines, while policy shifts and tariff dynamics in 2025 have underscored the importance of supply chain agility and supplier diversification. By approaching packaging decisions through layered segmentation - evaluating packaging type, temperature range, application, end-user needs, shipping mode, and insulation materials in combination - organizations can tailor solutions that protect product integrity and align with operational realities.

Looking forward, firms that combine validated technical performance with robust monitoring, flexible sourcing, and sustainability-minded lifecycle planning will be best positioned to manage uncertainty and protect patient outcomes. Cross-industry collaboration, early regulatory engagement, and investment in continuous assurance capabilities will further accelerate adoption of higher-performing systems. Ultimately, thoughtful packaging strategy is not merely a cost center but a differentiator that preserves therapeutic value, reduces clinical risk, and supports reliable access to temperature-sensitive medicines across global markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Temperature Controlled Package for Pharmaceutical Market, by Packaging Type

  • 8.1. Active Packaging
    • 8.1.1. Electric Coolers
    • 8.1.2. Phase Change Materials
    • 8.1.3. Refrigeration Units
  • 8.2. Passive Packaging
    • 8.2.1. Dry Ice
    • 8.2.2. Foam Insulation
    • 8.2.3. Gel Packs

9. Temperature Controlled Package for Pharmaceutical Market, by Temperature Range

  • 9.1. Controlled Ambient
  • 9.2. Frozen
  • 9.3. Refrigerated

10. Temperature Controlled Package for Pharmaceutical Market, by Shipping Mode

  • 10.1. Air Freight
  • 10.2. Ground Transportation
  • 10.3. Sea Freight

11. Temperature Controlled Package for Pharmaceutical Market, by Insulation Material

  • 11.1. Expanded Polystyrene
  • 11.2. Gel Pack Inserts
  • 11.3. Polyurethane Foam
  • 11.4. Vacuum Insulated Panels

12. Temperature Controlled Package for Pharmaceutical Market, by Application

  • 12.1. Biologics
    • 12.1.1. Monoclonal Antibodies
    • 12.1.2. Recombinant Proteins
  • 12.2. Insulin
  • 12.3. Sterile Injectables
  • 12.4. Vaccines
    • 12.4.1. Mrna Vaccines
    • 12.4.2. Protein Subunit Vaccines
    • 12.4.3. Viral Vector Vaccines

13. Temperature Controlled Package for Pharmaceutical Market, by End User

  • 13.1. Contract Research Organizations
  • 13.2. Healthcare Facilities
  • 13.3. Logistics Providers
  • 13.4. Pharmaceutical Manufacturers

14. Temperature Controlled Package for Pharmaceutical Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Temperature Controlled Package for Pharmaceutical Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Temperature Controlled Package for Pharmaceutical Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Temperature Controlled Package for Pharmaceutical Market

18. China Temperature Controlled Package for Pharmaceutical Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Air Liquide S.A.
  • 19.6. Cold Chain Technologies, LLC
  • 19.7. Cryopak Industries Inc.
  • 19.8. Cryoport, Inc
  • 19.9. Envirotainer AB
  • 19.10. Pelican Products, Inc
  • 19.11. Sealed Air Corporation
  • 19.12. Softbox Solutions Ltd
  • 19.13. Sonoco Products Company
  • 19.14. Thermo Fisher Scientific Inc.
  • 19.15. Va-Q-tec AG
  • 19.16. World Courier, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ELECTRIC COOLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ELECTRIC COOLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ELECTRIC COOLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHASE CHANGE MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHASE CHANGE MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHASE CHANGE MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATION UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATION UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATION UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY DRY ICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY DRY ICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY DRY ICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FOAM INSULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FOAM INSULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FOAM INSULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTROLLED AMBIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTROLLED AMBIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTROLLED AMBIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FROZEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FROZEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REFRIGERATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY AIR FREIGHT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY AIR FREIGHT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY AIR FREIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUND TRANSPORTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUND TRANSPORTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUND TRANSPORTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SEA FREIGHT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SEA FREIGHT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SEA FREIGHT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY EXPANDED POLYSTYRENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY EXPANDED POLYSTYRENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY EXPANDED POLYSTYRENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACK INSERTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACK INSERTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GEL PACK INSERTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY POLYURETHANE FOAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY POLYURETHANE FOAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY POLYURETHANE FOAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACUUM INSULATED PANELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACUUM INSULATED PANELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACUUM INSULATED PANELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY STERILE INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY STERILE INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY STERILE INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY HEALTHCARE FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY HEALTHCARE FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY HEALTHCARE FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY LOGISTICS PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY LOGISTICS PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY LOGISTICS PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 209. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 210. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 213. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 214. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 216. GCC TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 242. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PASSIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 243. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY SHIPPING MODE, 2018-2032 (USD MILLION)
  • TABLE 245. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY INSULATION MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. NATO TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKET SIZE, BY ACTIVE PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 253. NATO TEMPERATURE CONTROLLED PACKAGE FOR PHARMACEUTICAL MARKE